Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

MELOXICAM

All products: general benefit

Other products in the same Health Canada class (M01A, M01AC) — coverage varies; not interchangeable

  • Piroxicam (Feldene): general benefit, Not a benefit
  • Diclofenac (Voltaren): general benefit, Not a benefit
  • Diclofenac + misoprostol (Arthrotec 50): general benefit
  • Flurbiprofen (Ansaid): general benefit, Not a benefit
  • Ibuprofen (Motrin): general benefit, Not a benefit
  • Indomethacin (Indocid): general benefit, Not a benefit

12 more in the class list below

PMS-Meloxicam · DIN 02248267 · 7.5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Meloxicam · DIN 02248267 Manufacturer: Pharmascience Inc.; listing date 2004-04-06 Health Canada: Marketed since 2003-11-07 · brand PMS-MELOXICAM · ATC M01AC06 MELOXICAM · form Tablet · route Oral · ingredients MELOXICAM 7.5 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Meloxicam: Formulary list price $0.2003/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2003 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72606 · Verify on the e-Formulary ↗ (DIN 02248267)

Source record
DIN 02248267: PMS-Meloxicam Raw flags: sec3=Y Item: 280804083; group id 387; item number 0925; lccId None; manufacturer id PMS Source form: Tab; strength: 7.5mg Recorded listing: General benefit Source prices (unrounded): $0.2003; ministry $0.2003 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248267 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72606 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Meloxicam · DIN 02248973 · $0.2003 Auro-Meloxicam · DIN 02390884 · $0.2003 Co Meloxicam · DIN 02250012 · $0.2003 Meloxicam · DIN 02353148 · $0.2003 Mobicox · DIN 02242785 · not recorded Teva-Meloxicam · DIN 02258315 · $0.2003
Shortage status: discontinued (2020-06-15, reported by PHARMASCIENCE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248267
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:08:04 Nonsteroidal Anti-Inflammatory Agents) and how they are covered

Matched class: 28:08:04 Nonsteroidal Anti-Inflammatory Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DICLOFENAC SODIUM & MISOPROSTOL Some products covered without a code (check the product listing): DICLOFENAC SODIUM, FLURBIPROFEN, IBUPROFEN, INDOMETHACIN, KETOPROFEN, MEFENAMIC ACID, NAPROXEN, PIROXICAM, SULINDAC, TIAPROFENIC ACID 28:08:04 Nonsteroidal Anti-Inflammatory Agents

PIROXICAM

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 10mg, 20mg · Cap

DICLOFENAC SODIUM

· 19 products · Listed, not a benefit (3), General benefit (11), Off-Formulary Interchangeable, not an ODB benefit (5) · strengths: 25mg, 50mg, 75mg, 100mg, 1.5% W/W · Ent Tab, LA Tab, Sup, Top Sol

DICLOFENAC SODIUM & MISOPROSTOL

· 6 products · General benefit · strengths: 50mg & 200mcg, 75mg & 200mcg · Tab

FLURBIPROFEN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50mg, 100mg · Tab

IBUPROFEN

· 11 products · Listed, not a benefit (3), General benefit (8) · strengths: 200mg, 300mg, 400mg, 600mg · Tab

INDOMETHACIN

· 10 products · Listed, not a benefit (4), General benefit (6) · strengths: 25mg, 50mg, 100mg · Cap, Sup

KETOPROFEN

· 9 products · General benefit (4), Listed, not a benefit (5) · strengths: 50mg, 100mg, 200mg · Cap, Ent Tab, LA Tab

MEFENAMIC ACID

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Cap

NAPROXEN

· 21 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (8), Listed, not a benefit (4) · strengths: 250mg, 375mg, 500mg, 25mg/mL, 125mg · Ent Tab, O/L, Tab

SULINDAC

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 150mg, 200mg · Tab

TIAPROFENIC ACID

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 200mg, 300mg · Tab

CELECOXIB

· 36 products · Limited Use, codes 316, 317 · strengths: 100mg, 200mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:08:04 and 6 more
Full class listing Related classes: 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: the symptomatic treatment of
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. PIROXICAM · Listed, not a benefit (2), General benefit (4) 1 INDICATIONS APO-PIROXICAM (piroxicam) is indicated for the symptomatic treatment of: • rheumatoid arthritis, • osteoarthritis (degenerative joint disease) and • ankylosing spondylitis. PM: https://pdf.hres.ca/dpd_pm/00071325.PDF; date MAY 16, 2023; DIN 00642886; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE pms-MELOXICAM (meloxicam) is indicated for the symptomatic treatment of:  Rheumatoid arthritis in adults, and  Painful osteoarthritis (arthrosis, degenerative joint disease) in adults Throughout this document, the term NSAIDs refers to both non-selective NSAIDs and selective COX-2 inhibitor NSAIDs, unless otherwise indicated. For patients with an increased risk of developing CV and/or GI adverse events, other management strategies that do NOT include the use of NSAIDs should be considered first (see CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS). Use of pms-MELOXICAM should be limited to the lowest effective dose for the shortest possible duration of treatment in order to minimize the potential risk for cardiovascular or gastrointestinal adverse events (see CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS). pms-MELOXICAM, as a NSAID, does NOT treat clinical disease or prevent its progression. pms-MELOXICAM, as a NSAID, only relieves symptoms and decreases inflammation for as long as the patient continues to take it. Geriatrics (> 65 years of age): Evidence from clinical studies and post-market experience suggests that use in the geriatric … https://pdf.hres.ca/dpd_pm/00064407.PDF PM date: January 19, 2022 Source product: PMS-MELOXICAM; DIN 02248267; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

PMS-Meloxicam · DIN 02248267 Shortage status: discontinued (2020-06-15, reported by PHARMASCIENCE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248267

Check this DIN again